PT  - JOURNAL ARTICLE
AU  - Shugri, Mohamed Abdirahman
AU  - Libe, Temesgen Teferi
AU  - Gebru, Feven Mekonnen
TI  - Retrospective Analysis of Neonatal Hyperbilirubinemia at Hiwot Fana Specialized Hospital, Ethiopia: Prevalence, Associated Factors, and Treatment Outcomes
AID  - 10.1101/2024.05.13.24307293
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.13.24307293
4099  - http://medrxiv.org/content/early/2024/05/13/2024.05.13.24307293.short
4100  - http://medrxiv.org/content/early/2024/05/13/2024.05.13.24307293.full
AB  - Background Neonatal hyperbilirubinemia, also known as neonatal jaundice, is a condition characterized by yellowish discoloration of the skin and eyes caused by bilirubin buildup in the body. Understanding its prevalence, associated factors, and outcomes is crucial for effective management.Objectives This study aimed to assess the prevalence, associated factors, and treatment outcomes of neonatal hyperbilirubinemia at Hiwot Fana Specialized Hospital, Eastern Ethiopia.Methodology A hospital-based cross-sectional study was conducted from December 1, 2020, to December 30, 2020, involving 328 neonates admitted to the Neonatal Intensive Care Unit. Data were collected using a checklist and analyzed using SPSS version 22.Result Neonatal hyperbilirubinemia prevalence was 44.2%, with 1.4% progressing to bilirubin encephalopathy. Sepsis (44.8%) and prematurity (22%) were major contributing factors. Most neonates were treated with phototherapy alone (82.3%), and 93.8% showed improvement.Conclusion The study underscores the importance of early detection and management of neonatal hyperbilirubinemia to prevent adverse outcomes. Recommendations include integrating jaundice prevention into antenatal care and ensuring timely bilirubin level checks in neonates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe thesis was funded by Jigjiga UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Institutional Research Ethics Review Committee (IHRERC) of Haramaya University. Informed consent was obtained from participants, and confidentiality was maintained throughout the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAny of the data used for analysis in the study is available from the corresponding author and ready to be provided up on reasonable request.